Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 11/2015

Open Access 01-11-2015 | Original Article

Empirical antibiotic therapy for pneumonia in intensive care units: a multicentre, retrospective analysis of potentially pathogenic microorganisms identified by endotracheal aspirates cultures

Authors: J. B. J. Scholte, H. L. Duong, C. Linssen, H. Van Dessel, D. Bergmans, R. van der Horst, P. Savelkoul, P. Roekaerts, W. van Mook

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 11/2015

Login to get access

Abstract

The purpose of this investigation was to explore the presumed relationship between the days of hospitalisation and microorganisms identified by endotracheal aspirate cultures in relation to adequate empirical treatment strategies of pneumonia in the intensive care unit (ICU). All potentially pathogenic microorganisms identified by (surveillance) cultures of endotracheal aspirates obtained in the ICUs of two Dutch teaching hospitals in 2007 and 2012 were retrospectively collected and analysed. Antibiotic susceptibilities to 11 antibiotics were calculated for several time points (days or weeks) after hospital admission and expressed per patient-day. In total, 4184 potentially pathogenic microorganisms identified in 782 patients were analysed. Prevalence of the classic early-onset pneumonia-causing microorganisms decreased from 55 % on the first four days to 34 % on days 4–6 after hospital admission (p < 0.0001). Susceptibility to amoxicillin/clavulanic acid was below 70 % on all days. Except for days 0 and 12, susceptibility to ceftriaxone was below 80 %. The overall susceptibility to piperacillin/tazobactam was 1518/1973 (77 %) in 2007 vs. 727/1008 (67 %) in 2012 (p < 0.0001). After day 8 of hospital admission, susceptibility to piperacillin/tazobactam therapy was below 80 % in 2012. After one week of hospital admission, susceptibilities to antibiotics were lower in the hospital that included that antibiotic in the local empirical treatment protocols as compared to the hospitals in which that antibiotic was not or infrequently included: 90/434 (21 %) vs. 117/398 (29 %); p = 0.004 for amoxicillin/clavulanic acid and 203/433 (47 %) vs. 253/398 (64 %); p < 0.001 for ceftriaxone. No cut-off in the number of days after hospital admission could be identified to distinguish early-onset from late-onset pneumonia. Consequently, the choice of empirical antibiotics should probably not be based on the time of onset.
Appendix
Available only for authorised users
Literature
1.
go back to reference Safdar N, Dezfulian C, Collard HR, Saint S (2005) Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 33(10):2184–2193CrossRefPubMed Safdar N, Dezfulian C, Collard HR, Saint S (2005) Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 33(10):2184–2193CrossRefPubMed
2.
go back to reference Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, Hanisch EW, Klarin B, Koeman M, Krueger WA, Lacherade JC, Lorente L, Memish ZA, Morrow LE, Nardi G, van Nieuwenhoven CA, O’Keefe GE, Nakos G, Scannapieco FA, Seguin P, Staudinger T, Topeli A, Ferrer M, Bonten MJ (2013) Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 13(8):665–671CrossRefPubMed Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, Hanisch EW, Klarin B, Koeman M, Krueger WA, Lacherade JC, Lorente L, Memish ZA, Morrow LE, Nardi G, van Nieuwenhoven CA, O’Keefe GE, Nakos G, Scannapieco FA, Seguin P, Staudinger T, Topeli A, Ferrer M, Bonten MJ (2013) Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 13(8):665–671CrossRefPubMed
3.
go back to reference Luna CM, Aruj P, Niederman MS, Garzón J, Violi D, Prignoni A, Ríos F, Baquero S, Gando S; Grupo Argentino de Estudio de la Neumonía Asociada al Respirador group (2006) Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 27(1):158–164CrossRefPubMed Luna CM, Aruj P, Niederman MS, Garzón J, Violi D, Prignoni A, Ríos F, Baquero S, Gando S; Grupo Argentino de Estudio de la Neumonía Asociada al Respirador group (2006) Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 27(1):158–164CrossRefPubMed
4.
go back to reference Kollef MH, Fraser VJ (2001) Antibiotic resistance in the intensive care unit. Ann Intern Med 134(4):298–314CrossRefPubMed Kollef MH, Fraser VJ (2001) Antibiotic resistance in the intensive care unit. Ann Intern Med 134(4):298–314CrossRefPubMed
5.
go back to reference Society for Healthcare Epidemiology of America; Infectious Diseases Society of America; Pediatric Infectious Diseases Society (2012) Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 33(4):322–327CrossRef Society for Healthcare Epidemiology of America; Infectious Diseases Society of America; Pediatric Infectious Diseases Society (2012) Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 33(4):322–327CrossRef
6.
go back to reference American Thoracic Society; Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171(4):388–416CrossRef American Thoracic Society; Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171(4):388–416CrossRef
7.
go back to reference Langer M, Cigada M, Mandelli M, Mosconi P, Tognoni G (1987) Early onset pneumonia: a multicenter study in intensive care units. Intensive Care Med 13(5):342–346CrossRefPubMed Langer M, Cigada M, Mandelli M, Mosconi P, Tognoni G (1987) Early onset pneumonia: a multicenter study in intensive care units. Intensive Care Med 13(5):342–346CrossRefPubMed
8.
go back to reference Restrepo MI, Peterson J, Fernandez JF, Qin Z, Fisher AC, Nicholson SC (2013) Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies. Respir Care 58(7):1220–1225PubMedCentralCrossRefPubMed Restrepo MI, Peterson J, Fernandez JF, Qin Z, Fisher AC, Nicholson SC (2013) Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies. Respir Care 58(7):1220–1225PubMedCentralCrossRefPubMed
9.
go back to reference Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E, Kartali-Ktenidou S, Minopoulos GI, Zakynthinos S, Manolas KI (2005) Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria. Intensive Care Med 31(11):1488–1494CrossRefPubMed Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E, Kartali-Ktenidou S, Minopoulos GI, Zakynthinos S, Manolas KI (2005) Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria. Intensive Care Med 31(11):1488–1494CrossRefPubMed
10.
go back to reference Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C (1998) Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157(2):531–539CrossRefPubMed Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C (1998) Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157(2):531–539CrossRefPubMed
11.
go back to reference Gastmeier P, Sohr D, Geffers C, Rüden H, Vonberg RP, Welte T (2009) Early- and late-onset pneumonia: is this still a useful classification? Antimicrob Agents Chemother 53(7):2714–2718PubMedCentralCrossRefPubMed Gastmeier P, Sohr D, Geffers C, Rüden H, Vonberg RP, Welte T (2009) Early- and late-onset pneumonia: is this still a useful classification? Antimicrob Agents Chemother 53(7):2714–2718PubMedCentralCrossRefPubMed
13.
go back to reference Brusselaers N, Labeau S, Vogelaers D, Blot S (2013) Value of lower respiratory tract surveillance cultures to predict bacterial pathogens in ventilator-associated pneumonia: systematic review and diagnostic test accuracy meta-analysis. Intensive Care Med 39(3):365–375CrossRefPubMed Brusselaers N, Labeau S, Vogelaers D, Blot S (2013) Value of lower respiratory tract surveillance cultures to predict bacterial pathogens in ventilator-associated pneumonia: systematic review and diagnostic test accuracy meta-analysis. Intensive Care Med 39(3):365–375CrossRefPubMed
14.
go back to reference Muscedere J, Dodek P, Keenan S, Fowler R, Cook D, Heyland D; VAP Guidelines Committee and the Canadian Critical Care Trials Group (2008) Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment. J Crit Care 23(1):138–147CrossRefPubMed Muscedere J, Dodek P, Keenan S, Fowler R, Cook D, Heyland D; VAP Guidelines Committee and the Canadian Critical Care Trials Group (2008) Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment. J Crit Care 23(1):138–147CrossRefPubMed
15.
go back to reference Magill SS, Klompas M, Balk R, Burns SM, Deutschman CS, Diekema D, Fridkin S, Greene L, Guh A, Gutterman D, Hammer B, Henderson D, Hess D, Hill NS, Horan T, Kollef M, Levy M, Septimus E, VanAntwerpen C, Wright D, Lipsett P (2013) Developing a new, national approach to surveillance for ventilator-associated events*. Crit Care Med 41(11):2467–2475CrossRefPubMed Magill SS, Klompas M, Balk R, Burns SM, Deutschman CS, Diekema D, Fridkin S, Greene L, Guh A, Gutterman D, Hammer B, Henderson D, Hess D, Hill NS, Horan T, Kollef M, Levy M, Septimus E, VanAntwerpen C, Wright D, Lipsett P (2013) Developing a new, national approach to surveillance for ventilator-associated events*. Crit Care Med 41(11):2467–2475CrossRefPubMed
16.
go back to reference De Bus L, Saerens L, Gadeyne B, Boelens J, Claeys G, De Waele JJ, Benoit DD, Decruyenaere J, Depuydt PO (2014) Development of antibiotic treatment algorithms based on local ecology and respiratory surveillance cultures to restrict the use of broad-spectrum antimicrobial drugs in the treatment of hospital-acquired pneumonia in the intensive care unit: a retrospective analysis. Crit Care 18(4):R152PubMedCentralCrossRefPubMed De Bus L, Saerens L, Gadeyne B, Boelens J, Claeys G, De Waele JJ, Benoit DD, Decruyenaere J, Depuydt PO (2014) Development of antibiotic treatment algorithms based on local ecology and respiratory surveillance cultures to restrict the use of broad-spectrum antimicrobial drugs in the treatment of hospital-acquired pneumonia in the intensive care unit: a retrospective analysis. Crit Care 18(4):R152PubMedCentralCrossRefPubMed
17.
go back to reference Scholte JB, van Mook WN, Linssen CF, van Dessel HA, Bergmans DC, Savelkoul PH, Roekaerts PM (2014) Surveillance cultures in intensive care units: a nationwide survey on current practice providing future perspectives. J Crit Care 29(5):885.e7–885.e12CrossRef Scholte JB, van Mook WN, Linssen CF, van Dessel HA, Bergmans DC, Savelkoul PH, Roekaerts PM (2014) Surveillance cultures in intensive care units: a nationwide survey on current practice providing future perspectives. J Crit Care 29(5):885.e7–885.e12CrossRef
18.
go back to reference European Centre for Disease Prevention and Control (ECDC) (2013) Antimicrobial Resistance Surveillance in Europe. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net), 2012. Stockholm, Sweden European Centre for Disease Prevention and Control (ECDC) (2013) Antimicrobial Resistance Surveillance in Europe. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net), 2012. Stockholm, Sweden
19.
go back to reference Kariv G, Paul M, Shani V, Muchtar E, Leibovici L (2013) Benchmarking inappropriate empirical antibiotic treatment. Clin Microbiol Infect 19(7):629–633CrossRefPubMed Kariv G, Paul M, Shani V, Muchtar E, Leibovici L (2013) Benchmarking inappropriate empirical antibiotic treatment. Clin Microbiol Infect 19(7):629–633CrossRefPubMed
20.
go back to reference Leclercq R, Cantón R, Brown DF, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G (2013) EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19(2):141–160CrossRefPubMed Leclercq R, Cantón R, Brown DF, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G (2013) EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19(2):141–160CrossRefPubMed
21.
go back to reference National Institute for Public Health and the Environment (SWAB) TDWPoAP (2012) Nethmap 2012: consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands. pp 1–63 National Institute for Public Health and the Environment (SWAB) TDWPoAP (2012) Nethmap 2012: consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands. pp 1–63
22.
go back to reference Canadian Critical Care Trials Group (2006) A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 355(25):2619–2630CrossRef Canadian Critical Care Trials Group (2006) A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 355(25):2619–2630CrossRef
23.
go back to reference Medford AR, Husain SA, Turki HM, Millar AB (2009) Diagnosis of ventilator-associated pneumonia. J Crit Care 24(3):473.e1–473.e6CrossRef Medford AR, Husain SA, Turki HM, Millar AB (2009) Diagnosis of ventilator-associated pneumonia. J Crit Care 24(3):473.e1–473.e6CrossRef
25.
go back to reference Guyot A, Turton JF, Garner D (2013) Outbreak of Stenotrophomonas maltophilia on an intensive care unit. J Hosp Infect 85(4):303–307CrossRefPubMed Guyot A, Turton JF, Garner D (2013) Outbreak of Stenotrophomonas maltophilia on an intensive care unit. J Hosp Infect 85(4):303–307CrossRefPubMed
26.
go back to reference Brooke JS (2014) New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen. Expert Rev Anti Infect Ther 12(1):1–4CrossRefPubMed Brooke JS (2014) New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen. Expert Rev Anti Infect Ther 12(1):1–4CrossRefPubMed
27.
go back to reference van de Voort PHJ, van Saene HKF (2008) Selective digestive tract decontamination in intensive care medicine: a practical guide to controlling infection. Springer, MilanCrossRef van de Voort PHJ, van Saene HKF (2008) Selective digestive tract decontamination in intensive care medicine: a practical guide to controlling infection. Springer, MilanCrossRef
28.
go back to reference Vegelin AL, Bissumbhar P, Joore JC, Lammers JW, Hoepelman IM (1999) Guidelines for severe community-acquired pneumonia in the western world. Neth J Med 55(3):110–117CrossRefPubMed Vegelin AL, Bissumbhar P, Joore JC, Lammers JW, Hoepelman IM (1999) Guidelines for severe community-acquired pneumonia in the western world. Neth J Med 55(3):110–117CrossRefPubMed
29.
go back to reference Vogelaers D, De Bels D, Forêt F, Cran S, Gilbert E, Schoonheydt K, Blot S; ANTHICUS Study Investigators (2010) Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates—a multicentre, observational survey in critically ill patients. Int J Antimicrob Agents 35(4):375–381 Vogelaers D, De Bels D, Forêt F, Cran S, Gilbert E, Schoonheydt K, Blot S; ANTHICUS Study Investigators (2010) Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates—a multicentre, observational survey in critically ill patients. Int J Antimicrob Agents 35(4):375–381
30.
go back to reference Nair GB, Niederman MS (2015) Ventilator-associated pneumonia: present understanding and ongoing debates. Intensive Care Med 41(1):34–48CrossRefPubMed Nair GB, Niederman MS (2015) Ventilator-associated pneumonia: present understanding and ongoing debates. Intensive Care Med 41(1):34–48CrossRefPubMed
31.
go back to reference Scholte JB, van Mook WN, Linssen CF (2014) Surveillance cultures in healthcare-associated pneumonia: sense or nonsense? Curr Opin Pulm Med 20(3):259–271CrossRefPubMed Scholte JB, van Mook WN, Linssen CF (2014) Surveillance cultures in healthcare-associated pneumonia: sense or nonsense? Curr Opin Pulm Med 20(3):259–271CrossRefPubMed
32.
go back to reference Rodvold KA, George JM, Yoo L (2011) Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet 50(10):637–664CrossRefPubMed Rodvold KA, George JM, Yoo L (2011) Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet 50(10):637–664CrossRefPubMed
33.
go back to reference Schacht J, Talaska AE, Rybak LP (2012) Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention. Anat Rec (Hoboken) 295(11):1837–1850CrossRef Schacht J, Talaska AE, Rybak LP (2012) Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention. Anat Rec (Hoboken) 295(11):1837–1850CrossRef
34.
go back to reference Swan SK (1997) Aminoglycoside nephrotoxicity. Semin Nephrol 17(1):27–33PubMed Swan SK (1997) Aminoglycoside nephrotoxicity. Semin Nephrol 17(1):27–33PubMed
35.
go back to reference Kahlmeter G, Dahlager JI (1984) Aminoglycoside toxicity—a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 13(Suppl A):9–22CrossRefPubMed Kahlmeter G, Dahlager JI (1984) Aminoglycoside toxicity—a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 13(Suppl A):9–22CrossRefPubMed
36.
go back to reference Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y (2003) Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 9(11):1415–1422PubMedCentralCrossRefPubMed Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y (2003) Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 9(11):1415–1422PubMedCentralCrossRefPubMed
37.
go back to reference Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L (2005) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41(9):1254–1260CrossRefPubMed Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L (2005) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41(9):1254–1260CrossRefPubMed
38.
go back to reference de With K, Steib-Bauert M, Straach P, Kern WV (2006) Is there significant regional variation in hospital antibiotic consumption in Germany? Infection 34(5):274–277CrossRefPubMed de With K, Steib-Bauert M, Straach P, Kern WV (2006) Is there significant regional variation in hospital antibiotic consumption in Germany? Infection 34(5):274–277CrossRefPubMed
39.
go back to reference Chaouch C, Hassairi A, Riba M, Boujaafar N (2014) Association between bacterial resistance and antimicrobial consumption. Ann Biol Clin (Paris) 72(5):555–560 Chaouch C, Hassairi A, Riba M, Boujaafar N (2014) Association between bacterial resistance and antimicrobial consumption. Ann Biol Clin (Paris) 72(5):555–560
40.
go back to reference Meyer E, Gastmeier P, Deja M, Schwab F (2013) Antibiotic consumption and resistance: data from Europe and Germany. Int J Med Microbiol 303(6–7):388–395CrossRefPubMed Meyer E, Gastmeier P, Deja M, Schwab F (2013) Antibiotic consumption and resistance: data from Europe and Germany. Int J Med Microbiol 303(6–7):388–395CrossRefPubMed
41.
go back to reference Raineri E, Crema L, Dal Zoppo S, Acquarolo A, Pan A, Carnevale G, Albertario F, Candiani A (2010) Rotation of antimicrobial therapy in the intensive care unit: impact on incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 29(8):1015–1024CrossRefPubMed Raineri E, Crema L, Dal Zoppo S, Acquarolo A, Pan A, Carnevale G, Albertario F, Candiani A (2010) Rotation of antimicrobial therapy in the intensive care unit: impact on incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 29(8):1015–1024CrossRefPubMed
42.
go back to reference Merz LR, Warren DK, Kollef MH, Fridkin SK, Fraser VJ (2006) The impact of an antibiotic cycling program on empirical therapy for Gram-negative infections. Chest 130(6):1672–1678CrossRefPubMed Merz LR, Warren DK, Kollef MH, Fridkin SK, Fraser VJ (2006) The impact of an antibiotic cycling program on empirical therapy for Gram-negative infections. Chest 130(6):1672–1678CrossRefPubMed
43.
go back to reference Hughes MG, Evans HL, Chong TW, Smith RL, Raymond DP, Pelletier SJ, Pruett TL, Sawyer RG (2004) Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infections on the non-intensive care unit ward. Crit Care Med 32(1):53–60CrossRefPubMed Hughes MG, Evans HL, Chong TW, Smith RL, Raymond DP, Pelletier SJ, Pruett TL, Sawyer RG (2004) Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infections on the non-intensive care unit ward. Crit Care Med 32(1):53–60CrossRefPubMed
44.
go back to reference Beardsley JR, Williamson JC, Johnson JW, Ohl CA, Karchmer TB, Bowton DL (2006) Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 130(3):787–793CrossRefPubMed Beardsley JR, Williamson JC, Johnson JW, Ohl CA, Karchmer TB, Bowton DL (2006) Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 130(3):787–793CrossRefPubMed
45.
go back to reference Becher RD, Hoth JJ, Rebo JJ, Kendall JL, Miller PR (2012) Locally derived versus guideline-based approach to treatment of hospital-acquired pneumonia in the trauma intensive care unit. Surg Infect (Larchmt) 13(6):352–359CrossRef Becher RD, Hoth JJ, Rebo JJ, Kendall JL, Miller PR (2012) Locally derived versus guideline-based approach to treatment of hospital-acquired pneumonia in the trauma intensive care unit. Surg Infect (Larchmt) 13(6):352–359CrossRef
46.
go back to reference Hindler JF, Stelling J (2007) Analysis and presentation of cumulative antibiograms: a new consensus guideline from the Clinical and Laboratory Standards Institute. Clin Infect Dis 44(6):867–873CrossRefPubMed Hindler JF, Stelling J (2007) Analysis and presentation of cumulative antibiograms: a new consensus guideline from the Clinical and Laboratory Standards Institute. Clin Infect Dis 44(6):867–873CrossRefPubMed
Metadata
Title
Empirical antibiotic therapy for pneumonia in intensive care units: a multicentre, retrospective analysis of potentially pathogenic microorganisms identified by endotracheal aspirates cultures
Authors
J. B. J. Scholte
H. L. Duong
C. Linssen
H. Van Dessel
D. Bergmans
R. van der Horst
P. Savelkoul
P. Roekaerts
W. van Mook
Publication date
01-11-2015
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 11/2015
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-015-2482-y

Other articles of this Issue 11/2015

European Journal of Clinical Microbiology & Infectious Diseases 11/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine